Clinical Trial Detail

NCT ID NCT02154776
Title Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements yes
Sponsors Novartis Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Buparlisib + Letrozole + Ribociclib

Age Groups: adult

Additional content available in CKB BOOST